SELENOP and metabolic dysfunction-associated steatotic liver disease: The same observations may be related to SeP, which has also shown a direct metabolic link to NAFLD, increasing circulating LDL levels and facilitating the development of insulin resistance (Petta et al., 2016; Kitade et al., 2017).